产品详情
简单介绍：
重组人上皮调节蛋白蛋白与其它公司提供的重组蛋白不同，rHuEpiregulin蛋白产品为采用CFS的无细胞麦胚蛋白合成系统表达出来的重组蛋白，可表达出对细胞有毒性、易被蛋白酶降解的蛋白；并获得具有良好的可溶性，并有翻译后修饰、从而部分具有功能的蛋白.同时独有的全自动蛋白纯化技术则简便高效，将蛋白纯化过程中对蛋白的损伤降低到*小程度.重组人上皮调节蛋白蛋白（全长序列）产品可用于Western Blot验证、抗体制备、蛋白检测、ELISA等试验中.
详情介绍：
重组人上皮调节蛋白蛋白
| Synonyms | EREG |
| Species | Human |
| Accession | O14944 |
| GeneID | 2069 |
| Source | Escherichia coli. |
| Molecular Weight | 重组人上皮调节蛋白蛋白Approximately 5.6 kDa, a single non-glycosylated polypeptide chain containing 49 amino acids. |
| Quantity | 5µg/25µg/1000µg |
| AA Sequence | VAQVSITKCS SDMNGYCLHG QCIYLVDMSQ NYCRCEVGYT GVRCEHFFL |
| Purity | > 97 % by SDS-PAGE and HPLC analyses. |
| Biological Activity | 重组人上皮调节蛋白蛋白Fully biologically active when compared to standard. The ED50as determined by a cell proliferation assay using murine Balb/c 3T3 cells is less than 2 ng/ml, corresponding to a specific activity of > 5.0 × 105IU/mg. |
| Physical Appearance | Sterile Filtered White lyophilized (freeze-dried) powder. |
| Formulation | Lyophilized from a 0.2 μm filtered concentrated solution in PBS, pH 7.4. |
| Endotoxin | Less than 1 EU/μg of rHuEpiregulin as determined by LAL method. |
| Reconstitution | 重组人上皮调节蛋白蛋白We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions. |
| Storage | This lyophilized preparation is stable at 2-8 °C, but should be kept at -20 °C for long term storage, preferably desiccated. Upon reconstitution, the preparation is stable for up to one week at 2-8 °C. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20 °C to -70 °C. Avoid repeated freeze/thaw cycles. |
| 重组人上皮调节蛋白蛋白 | |
| Reference | 1. Xi QS, Qian XG, Zhou QW, et al. 2000. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai), 32: 295-8. 2. Kuntz E, Broca C, Komurasaki T, et al. 2005. Growth Factors, 23: 285-93. 3. Shirakata Y, Kishimoto J, Tokumaru S, et al. 2007. J Dermatol Sci, 45: 69-72. 4. Thuong NT, Hawn TR, Chau TT, et al. 2012. Genes Immun, 13: 275-81. |
| Background | Epiregulin encoded by the EREG gene in humans, is a member of the EGF family of growth factors. This family also includes epidermal growth factor (EGF), transforming growth factor (TGF)-alpha, amphiregulin (ARG), HB (heparin-binding)-EGF, betacellulin, and the various heregulins. Epiregulin is expressed mainly in the placenta and peripheral blood leukocytes and in certain carcinomas of the bladder, lung, kidney and colon. It stimulates the proliferation of keratinocytes, hepatocytes, fibroblasts and vascular smooth muscle cells. Additionally, it inhibits the growth of several tumor-derived epithelial cell lines. Human Epiregulin is initially synthesized as a glycosylated 19.0 kDa transmembrane precursor protein, which is processed by proteolytic cleavage to produce a 6.0 kDa mature secreted sequence. |
